Salvestrini, ViolaCaini, SaverioScricciolo, MelissaSaerens, MichaelBollen, HeleenBonomo, PierluigiCaparrotti, FrancescaLorini, LuigiOliva, MarcUrbanowicz Nijaki, MariaSzturz, Petr2024-07-152024-07-152024-05-102234-943Xhttps://hdl.handle.net/2445/214582Introduction: Over the past years, there has been a growing interest in the role of immunotherapy in locally advanced (LA) and recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). High-quality data from prospective trials are lacking for the elderly subpopulation. This systematic review and meta-analysis aims to review the efficacy and safety of immunotherapy in older patients. Methods: A systematic literature search was conducted. Randomized clinical trials providing outcome data on a subgroup of elderly (>65 years old) were available for meta-analysis. Primary outcomes of interest were OS and PFS for efficacy analysis. Results: Seven studies were included in the systematic review and four in the efficacy analysis. The pooled analysis of OS and PFS showed a consistent benefit (HR 0.78 and 0.91, respectively). Conclusions: Immunotherapy may be an effective and well-tolerated treatment option in the elderly population, but more prospective and randomized data are needed. Systematic Review Registration PROSPERO (CRD42022333891).9 p.application/pdfengcc by (c) Salvestrini, Viola et al., 2024http://creativecommons.org/licenses/by/3.0/es/ImmunoteràpiaCura de les persones gransImmunotheraphyElderly careinfo:eu-repo/semantics/article2024-06-25info:eu-repo/semantics/openAccess38800381